Clinical trials
MSS clinical trials
Below are recruiting mss clinical trials, each written for real people, not researchers. We’re tracking 47 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06456515Recruiting
Regorafenib, sintilimab, and electroacupuncture for advanced colorectal cancer
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
ChangzhouAges 18–75 - NCT07347951RecruitingPhase 2
New drug combo for rectal cancer patients who want to save their anus
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
Wenzhou, ZhejiangAges 18–75 - NCT07328087RecruitingEarly Phase 1
Personalized colon cancer vaccine trial for MSS stage 3 patients
This trial tests a custom-made vaccine designed from your tumor's genetic material. The vaccine is given alongside standard chemotherapy and an immunotherapy drug to try to prevent the cancer from coming back. It is for people with stage 3 colorectal cancer that has been fully removed by surgery and has certain high-risk features.
ThessalonikiAges Any age - NCT07281716RecruitingPhase 1/Phase 2
Immunotherapy combo for advanced colorectal cancer
This trial tests a combination of immunotherapy drugs for people with a specific type of colorectal cancer (MSS, or microsatellite stable) that has stopped responding to standard chemotherapy. The goal is to see if this new treatment can shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT07277322RecruitingPhase 1/Phase 2
Two immunotherapy drugs before surgery for MSS colorectal cancer with liver spots
This trial tests a combination of two immunotherapy drugs (Dupilumab and Toripalimab) before surgery for people with MSS colorectal cancer that has spread to the liver. The goal is to see if this treatment can shrink the liver tumors and help the body's immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT07154316RecruitingPhase 2
Short radiation plus drugs for MSS rectal cancer
This trial tests a shorter course of radiation therapy followed by a combination of chemotherapy, immunotherapy, and a pain-relief medication, compared to the standard approach. It is for people with a certain type of rectal cancer that has not spread.
Fuzhou, FujianAges 18–75 - NCT07150949RecruitingPhase 2
Comparing two radiation schedules with chemotherapy and immunotherapy for rectal cancer
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07105631Recruiting
Study of cediranib and immunotherapy in advanced colorectal cancer
This study looks at how patients with a certain type of advanced colorectal cancer (MSS-type) feel and do during treatment with a combo of cediranib and immunotherapy. It aims to learn about side effects, quality of life, and how well the treatment works in everyday practice.
Chengdu, SichuanAges 18 years+ - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT07068763RecruitingPhase 2
Short radiation plus drugs for early rectal cancer
This trial tests a combination of short-course radiation, chemotherapy (capecitabine), and two immunotherapy drugs (PD-1 and CTLA-4 inhibitors) for people with early-stage rectal cancer who want to avoid surgery and keep their anus. The goal is to see if this treatment can shrink the tumor enough to avoid major surgery.
Hangzhou, ZhejiangAges 18–80 - NCT06864013RecruitingPhase 2
Short course radiation with chemo and immunotherapy for rectal cancer
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
Hangzhou, ZhejiangAges 18–75 - NCT06849362Enrolling by invitation
Optimizing immunotherapy for advanced colorectal cancer
This study looks at how well different combinations of immunotherapy drugs work for advanced colorectal cancer that is MSS or MSI-L or pMMR. It reviews past patient records to see which treatments help control the disease and slow its growth.
Changsha, HunanAges Any age - NCT06850103RecruitingPhase 2
Chemo, radiation, and immunotherapy for advanced rectal cancer that has spread a little
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (serplulimab) for people with rectal cancer that has spread to just a few spots in the body (no more than 5 tumors in up to 2 locations). It aims to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT06801665RecruitingPhase 2
Combination therapy for advanced colorectal cancer with liver spread
This trial tests a new combination of treatments for advanced colorectal cancer that has spread to the liver. It aims to see if this combination can shrink tumors and help patients live longer.
ChangzhouAges 18–75 - NCT06634875RecruitingPhase 2
Test of isunakinra alone or with pembrolizumab for colorectal cancer
This trial tests a new drug combination (isunakinra plus pembrolizumab) for people with a specific type of colorectal cancer (MSS, RAS-mutated) that has a high tumor mutational burden. It may help if other treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT06567782RecruitingPhase 2
Immunotherapy plus chemotherapy vs. chemotherapy alone for stage 3 colon cancer
This trial tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (CAPEOX) is more effective than chemotherapy alone for people with a specific type of colon cancer (MMRp/MSS) that has not spread. It is given before surgery to shrink the tumor.
AalstAges 18 years+ - NCT05576480RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for rectal cancer without mismatch repair
This Phase 2 study tests penpulimab (an immunotherapy medicine) given with CAPEOX chemotherapy before surgery for rectal cancer that is “MSS” (not the mismatch-repair type). It aims to shrink the tumor and improve outcomes by treating before the operation.
Shanghai, None SelectedAges 18–75 - NCT06321081RecruitingPhase 2
Rechallenge combo for metastatic colorectal cancer
This trial tests a combination of three drugs (cetuximab, irinotecan, and envafolimab) as a ‘rechallenge’ – meaning if you had good results with cetuximab or irinotecan before, trying them again with a new drug might help shrink or control your cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06281405RecruitingPhase 2
CAPOX and immunotherapy with or without radiation for rectal cancer
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
ShanghaiAges 18–70 - NCT06204094RecruitingPhase 2
Preserving the anus with chemo, immunotherapy, and radiation for rectal cancer
This trial tests a treatment plan that combines chemotherapy, immunotherapy, and radiation before surgery for patients with middle or low rectal cancer. The goal is to shrink the tumor enough to avoid removing the anus, preserving bowel function.
Jinhua, ZhejiangAges 18–75 - NCT05959356RecruitingPhase 2
First-line treatment for left-sided metastatic colon cancer with specific tumor markers
This Phase 2 trial tests a combination of medicines (cetuximab, envafolimab, and chemotherapy) as the first treatment for certain left-sided metastatic colorectal cancers. It may help by slowing or shrinking the cancer in people whose tumor has no RAS/BRAF mutations and is microsatellite-stable (MSS).
Foshan, GuangdongAges 18 years+ - NCT05752136RecruitingPhase 3
Pre-surgery radiation plus immunotherapy and chemo for rectal cancer
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT05731726RecruitingPhase 2
New treatment before surgery for locally advanced rectal cancer
This trial tests whether giving serplulimab (an immune medicine) plus CAPEOX chemotherapy and celecoxib before surgery can shrink locally advanced rectal cancer and improve outcomes. It may help by increasing immune attack on the tumor while chemotherapy helps reduce the cancer before the operation.
Hangzhou, ZhejiangAges 18–75
Hear when a new MSS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mss?
- Yes. Clin2 currently lists 47 recruiting mss studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mss trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mss trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.